This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $176,712 to the University of Pittsburgh to develop a new mouse model for studying the role of the CD91 receptor in cancer immunosurveillance. The research aims to investigate how tumor-derived heat shock proteins (HSPs) engage CD91 on antigen-presenting cells (APCs) to prime robust T cell responses against emerging, nascent tumors. The project will use the new mouse model to distinguish the co-stimulatory signaling functions of CD91 from its other roles in cancer immunosurveillance. This work is intended to expand understanding of how the immune system detects and eliminates pre-cancerous cells before malignancies form, with potential implications for advancing cancer prevention and early intervention strategies. The award has a period of performance from March 2025 through February 2027.
Generated 3/25/25, 4:53 AM